Additional Payments Receivable On Milestone Achievements

No definition available.

Name:	aria_AdditionalPaymentsReceivableOnMilestoneAchievements
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Buy-in License Agreement, Royalty Payment Rate

+ References

No definition available.

+ Details

Name:	aria_BuyinLicenseAgreementRoyaltyPaymentRate
Namespace Prefix:	aria_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Disposal Group, Expected Working Capital Refund Adjustment

+ References

No definition available.

+ Details

Name:	aria_DisposalGroupExpectedWorkingCapitalRefundAdjustment
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Disposal Group, Working Capital Payment Adjustment

+ References

No definition available.

+ Details

Name:	aria_DisposalGroupWorkingCapitalPaymentAdjustment
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Divestiture of Interest in Consolidated Subsidiaries, Liabilities Transferred

+ References

No definition available.

+ Details

Name:	aria_DivestitureofInterestinConsolidatedSubsidiariesLiabilitiesTransferred
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License Arrangement with Counterparty, Contribution Receivable

+ References

No definition available.

+ Details

Name:	aria_LicenseArrangementwithCounterpartyContributionReceivableForYearOne
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License Arrangement with Counterparty, Contribution Receivable For Year Two

+ References

No definition available.

+ Details

Name:	aria_LicenseArrangementwithCounterpartyContributionReceivableForYearTwo
Namespace Prefix:	aria_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The excess amount received or due over net assets in a transaction accounted for as a divestiture where a subsidiary, business or operating assets are "sold" by the entity to a newly formed, thinly capitalized, highly leveraged buyer. This gain is not yet recognized and is disclosed on the balance sheet as an offset against the carrying amount of the securities received.

+ References

No definition available.

+ Details

Name:	us-gaap_DisposalGroupDeferredGainOnDisposal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2443-110228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

+ Details

Name:	us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (13)(g)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name:	us-gaap_GainOrLossOnSaleOfStockInSubsidiary
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=aria_IncyteCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=aria_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=aria_LicenseAgreementAcquirerOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=aria_ARIADPharmaceuticalsLuxembourgS.a.r.lMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Incyte Transaction (Details) - USD ($)			3 Months Ended		6 Months Ended
Incyte Transaction (Details) - USD ($)	Jun. 01, 2016	May 09, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Subsidiary, Sale of Stock [Line Items]
Proceeds from the Incyte transaction, net of $4,484 of cash transferred					$ 144,847,000	$ 0
Consideration allocated to sale of business					131,575,000	0
Loss from reclassification of currency translation adjustment and pension obligation adjustments to earnings upon sale of European operations					2,939,000	0
Net gain recorded on transaction			$ 128,664,000	$ 0	128,664,000	$ 0
Incyte \| License agreement
Subsidiary, Sale of Stock [Line Items]
Additional milestone payments (up to)		$ 135,000,000
Contribution receivable for funding trials in 2016 (up to)		7,000,000
Contribution receivable for funding trials in 2017 (up to)		$ 7,000,000.0
Incyte \| License agreement \| Minimum
Subsidiary, Sale of Stock [Line Items]
Royalty payment rate (as a percent)	32.00%
Incyte \| License agreement \| Maximum
Subsidiary, Sale of Stock [Line Items]
Royalty payment rate (as a percent)	50.00%
Incyte \| License Agreement Acquirer Option \| Minimum
Subsidiary, Sale of Stock [Line Items]
Royalty payment rate (as a percent)		20.00%
Incyte \| License Agreement Acquirer Option \| Maximum
Subsidiary, Sale of Stock [Line Items]
Royalty payment rate (as a percent)		25.00%
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] \| ARIAD Pharmaceuticals (Luxembourg) S.a.r.l [Member]
Subsidiary, Sale of Stock [Line Items]
Total consideration for the Incyte transaction (including upfront payment)		$ 140,000,000
Estimated adjusted working capital payment	$ 4,800,000
Proceeds from the Incyte transaction, net of $4,484 of cash transferred	144,800,000				150,500,000
Net liabilities transferred to Incyte	7,500,000
Expected refund related to final working capital adjustment	1,800,000
Consideration allocated to sale of business	131,600,000
Consideration allocated to undelivered elements	18,900,000
Loss from reclassification of currency translation adjustment and pension obligation adjustments to earnings upon sale of European operations	$ 2,900,000
Net gain recorded on transaction			$ 128,700,000		$ 128,700,000